Ambrisentan

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Exercise-induced Pulmonary Arterial Hypertension

Conditions

Exercise-induced Pulmonary Arterial Hypertension

Trial Timeline

Sep 1, 2008 → May 1, 2016

NCT ID

NCT01338636

About Ambrisentan

Ambrisentan is a approved stage product being developed by Gilead Sciences for Exercise-induced Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01338636. Target conditions include Exercise-induced Pulmonary Arterial Hypertension.

What happened to similar drugs?

1 of 7 similar drugs in Exercise-induced Pulmonary Arterial Hypertension were approved

Approved (1) Terminated (0) Active (6)

🔄Levalbuterol tartrate HFA MDI + PlaceboSumitomo PharmaPhase 3

🔄Budesonide/albuterol metered-dose inhaler 160/180 μg + Placebo metered-dose inhalerAstraZenecaPhase 3

🔄BenralizumabAstraZenecaPhase 3

✅Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified)OrganonApproved

🔄Comparator: Montelukast + Comparator: PlaceboOrganonPhase 3

🔄Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol)OrganonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01224210	Phase 3	Completed	Mar 1, 2010	Mar 1, 2020	Portopulmonary Hypertension
NCT01072669	Pre-clinical	Completed	Feb 1, 2010	Dec 1, 2010	Ischemia
NCT01093885	Pre-clinical	Completed	Feb 1, 2010	Jul 1, 2016	Systemic Sclerosis
NCT01051960	Approved	Completed	Mar 1, 2009	Jan 1, 2011	Systemic Sclerosis
NCT00840463	Approved	Terminated	Jan 1, 2009	Jan 1, 2014	Pulmonary Hypertension
NCT00777920	Phase 3	Completed	Nov 17, 2008	Sep 11, 2019	Pulmonary Hypertension
NCT00851929	Phase 2/3	Completed	Nov 1, 2008	Nov 1, 2011	Sarcoidosis
NCT01338636	Approved	Completed	Sep 1, 2008	May 1, 2016	Exercise-induced Pulmonary Arterial Hypertension
NCT00380068	Phase 3	Completed	Aug 1, 2006	May 1, 2009	Pulmonary Hypertension
NCT00423592	Phase 2	Completed	May 1, 2005	Mar 1, 2009	Pulmonary Hypertension
NCT00578786	Phase 3	Completed	Feb 1, 2004	Mar 1, 2010	Pulmonary Arterial Hypertension
NCT00091598	Phase 3	Completed	Jan 1, 2004	Feb 1, 2006	Pulmonary Hypertension
NCT00423202	Phase 3	Completed	Dec 1, 2003	Oct 1, 2005	Pulmonary Arterial Hypertension
NCT00423748	Phase 3	Completed	Dec 1, 2003	Feb 1, 2006	Pulmonary Arterial Hypertension
NCT00424021	Phase 2	Completed	Apr 1, 2003	Dec 1, 2009	Pulmonary Hypertension

Competing Products

10 competing products in Exercise-induced Pulmonary Arterial Hypertension

See all competitors

Product	Company	Stage	Hype Score
Levalbuterol tartrate HFA MDI + Placebo	Sumitomo Pharma	Phase 3	40
Budesonide/albuterol metered-dose inhaler 160/180 μg + Placebo metered-dose inhaler	AstraZeneca	Phase 3	40
Benralizumab	AstraZeneca	Phase 3	36
Administration of montelukast or placebo	Merck	Pre-clinical	18
Combination DSCG and Reproterol	Sanofi	Phase 2	35
Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified)	Organon	Approved	37
Comparator: Montelukast + Comparator: Placebo	Organon	Phase 3	34
Comparator: Montelukast + Comparator: Placebo	Organon	Phase 3	34
montelukast sodium + Comparator: placebo (unspecified)	Organon	Phase 1	23
Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol)	Organon	Phase 3	34